NCT02562807View on ClinicalTrials.gov

A Study of TAS-303 in Female Patients With Stress Urinary Incontinence

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

March 31, 2016

Conditions
Stress Urinary Incontinence
Interventions
DRUG

TAS-303 18mg single-dose

DRUG

Placebo 18mg single-dose

DRUG

TAS-303 9mg single-dose

DRUG

Placebo 9mg single-dose

Trial Locations (1)

Unknown

Taiho Pharmaceutical Co., Ltd selected site, Kumamoto

All Listed Sponsors
lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT02562807 - A Study of TAS-303 in Female Patients With Stress Urinary Incontinence | Biotech Hunter | Biotech Hunter